Three-month cumulative incidence of thromboembolism and bleeding after periprocedural anticoagulation management of arterial vascular bypass patients

Hosam Attaya, Waldemar E. Wysokinski, Thomas Bower, Scott Litin, Paul R. Daniels, Joshua Slusser, John A. Heit, Robert D. Mcbane

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The objective of this study was to determine 3-month cumulative incidence of peri-procedural thromboembolism (TE) including graft occlusion, and peri-procedural bleeding for chronically anticoagulated vascular bypass graft (BG) patients requiring temporary warfarin interruption for an invasive procedure. Appropriate peri-procedural management of patients receiving chronic warfarin therapy to preserve lower extremity arterial BG patency is unknown. In a protocol driven, cohort study design, all BG patients referred to the Mayo Clinic Thrombophilia Center for peri-procedural anticoagulation (1997-2007) were followed forward in time to estimate the 3-month cumulative incidence of TE and bleeding. Decisions to provide "bridging" low molecular weight heparin (LMWH) were individualized based on estimated risk of TE and bleeding. There were 78 BG patients (69 ± 10 years; 38 % women), of whom 73 % had a distal autogenous and 53 % had prosthetic BG; 45 % received antiplatelet therapy. Peri-procedural LMWH was prescribed for 77 % of patients and did not vary by BG distal anastomosis location or type. The 3-month cumulative incidence of TE was 5.1 % (95 % CI 1.4-12.6), including two BG occlusions, one DVT, and one myocardial infarction. Major bleeding occurred in 1 patient (1.28 %, 95 % CI 0.0-6.94). One patient died due to heart failure. TE and bleeding did not differ by bridging status. The 3-month cumulative incidence of TE among BG patients in whom warfarin is temporarily interrupted for an invasive procedure may be higher than in other "bridging" populations (atrial fibrillation, prosthetic heart valve, venous thromboembolism). This finding underscores the often tenuous nature of distal bypass grafts necessitating an aggressive approach to peri-procedural anticoagulation management.

Original languageEnglish (US)
Pages (from-to)100-106
Number of pages7
JournalJournal of Thrombosis and Thrombolysis
Volume35
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Thromboembolism
Blood Vessels
Hemorrhage
Transplants
Incidence
Warfarin
Low Molecular Weight Heparin
Thrombophilia
Heart Valves
Venous Thromboembolism
Atrial Fibrillation
Lower Extremity
Cohort Studies
Heart Failure
Myocardial Infarction

Keywords

  • Bridging therapy
  • Heparin
  • Low molecular weight heparin
  • Surgery
  • Vascular bypass graft
  • Warfarin

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Three-month cumulative incidence of thromboembolism and bleeding after periprocedural anticoagulation management of arterial vascular bypass patients. / Attaya, Hosam; Wysokinski, Waldemar E.; Bower, Thomas; Litin, Scott; Daniels, Paul R.; Slusser, Joshua; Heit, John A.; Mcbane, Robert D.

In: Journal of Thrombosis and Thrombolysis, Vol. 35, No. 1, 01.2013, p. 100-106.

Research output: Contribution to journalArticle

Attaya, Hosam ; Wysokinski, Waldemar E. ; Bower, Thomas ; Litin, Scott ; Daniels, Paul R. ; Slusser, Joshua ; Heit, John A. ; Mcbane, Robert D. / Three-month cumulative incidence of thromboembolism and bleeding after periprocedural anticoagulation management of arterial vascular bypass patients. In: Journal of Thrombosis and Thrombolysis. 2013 ; Vol. 35, No. 1. pp. 100-106.
@article{57f5906b7f90495dab4d6cf7ba0d8394,
title = "Three-month cumulative incidence of thromboembolism and bleeding after periprocedural anticoagulation management of arterial vascular bypass patients",
abstract = "The objective of this study was to determine 3-month cumulative incidence of peri-procedural thromboembolism (TE) including graft occlusion, and peri-procedural bleeding for chronically anticoagulated vascular bypass graft (BG) patients requiring temporary warfarin interruption for an invasive procedure. Appropriate peri-procedural management of patients receiving chronic warfarin therapy to preserve lower extremity arterial BG patency is unknown. In a protocol driven, cohort study design, all BG patients referred to the Mayo Clinic Thrombophilia Center for peri-procedural anticoagulation (1997-2007) were followed forward in time to estimate the 3-month cumulative incidence of TE and bleeding. Decisions to provide {"}bridging{"} low molecular weight heparin (LMWH) were individualized based on estimated risk of TE and bleeding. There were 78 BG patients (69 ± 10 years; 38 {\%} women), of whom 73 {\%} had a distal autogenous and 53 {\%} had prosthetic BG; 45 {\%} received antiplatelet therapy. Peri-procedural LMWH was prescribed for 77 {\%} of patients and did not vary by BG distal anastomosis location or type. The 3-month cumulative incidence of TE was 5.1 {\%} (95 {\%} CI 1.4-12.6), including two BG occlusions, one DVT, and one myocardial infarction. Major bleeding occurred in 1 patient (1.28 {\%}, 95 {\%} CI 0.0-6.94). One patient died due to heart failure. TE and bleeding did not differ by bridging status. The 3-month cumulative incidence of TE among BG patients in whom warfarin is temporarily interrupted for an invasive procedure may be higher than in other {"}bridging{"} populations (atrial fibrillation, prosthetic heart valve, venous thromboembolism). This finding underscores the often tenuous nature of distal bypass grafts necessitating an aggressive approach to peri-procedural anticoagulation management.",
keywords = "Bridging therapy, Heparin, Low molecular weight heparin, Surgery, Vascular bypass graft, Warfarin",
author = "Hosam Attaya and Wysokinski, {Waldemar E.} and Thomas Bower and Scott Litin and Daniels, {Paul R.} and Joshua Slusser and Heit, {John A.} and Mcbane, {Robert D.}",
year = "2013",
month = "1",
doi = "10.1007/s11239-012-0787-6",
language = "English (US)",
volume = "35",
pages = "100--106",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Three-month cumulative incidence of thromboembolism and bleeding after periprocedural anticoagulation management of arterial vascular bypass patients

AU - Attaya, Hosam

AU - Wysokinski, Waldemar E.

AU - Bower, Thomas

AU - Litin, Scott

AU - Daniels, Paul R.

AU - Slusser, Joshua

AU - Heit, John A.

AU - Mcbane, Robert D.

PY - 2013/1

Y1 - 2013/1

N2 - The objective of this study was to determine 3-month cumulative incidence of peri-procedural thromboembolism (TE) including graft occlusion, and peri-procedural bleeding for chronically anticoagulated vascular bypass graft (BG) patients requiring temporary warfarin interruption for an invasive procedure. Appropriate peri-procedural management of patients receiving chronic warfarin therapy to preserve lower extremity arterial BG patency is unknown. In a protocol driven, cohort study design, all BG patients referred to the Mayo Clinic Thrombophilia Center for peri-procedural anticoagulation (1997-2007) were followed forward in time to estimate the 3-month cumulative incidence of TE and bleeding. Decisions to provide "bridging" low molecular weight heparin (LMWH) were individualized based on estimated risk of TE and bleeding. There were 78 BG patients (69 ± 10 years; 38 % women), of whom 73 % had a distal autogenous and 53 % had prosthetic BG; 45 % received antiplatelet therapy. Peri-procedural LMWH was prescribed for 77 % of patients and did not vary by BG distal anastomosis location or type. The 3-month cumulative incidence of TE was 5.1 % (95 % CI 1.4-12.6), including two BG occlusions, one DVT, and one myocardial infarction. Major bleeding occurred in 1 patient (1.28 %, 95 % CI 0.0-6.94). One patient died due to heart failure. TE and bleeding did not differ by bridging status. The 3-month cumulative incidence of TE among BG patients in whom warfarin is temporarily interrupted for an invasive procedure may be higher than in other "bridging" populations (atrial fibrillation, prosthetic heart valve, venous thromboembolism). This finding underscores the often tenuous nature of distal bypass grafts necessitating an aggressive approach to peri-procedural anticoagulation management.

AB - The objective of this study was to determine 3-month cumulative incidence of peri-procedural thromboembolism (TE) including graft occlusion, and peri-procedural bleeding for chronically anticoagulated vascular bypass graft (BG) patients requiring temporary warfarin interruption for an invasive procedure. Appropriate peri-procedural management of patients receiving chronic warfarin therapy to preserve lower extremity arterial BG patency is unknown. In a protocol driven, cohort study design, all BG patients referred to the Mayo Clinic Thrombophilia Center for peri-procedural anticoagulation (1997-2007) were followed forward in time to estimate the 3-month cumulative incidence of TE and bleeding. Decisions to provide "bridging" low molecular weight heparin (LMWH) were individualized based on estimated risk of TE and bleeding. There were 78 BG patients (69 ± 10 years; 38 % women), of whom 73 % had a distal autogenous and 53 % had prosthetic BG; 45 % received antiplatelet therapy. Peri-procedural LMWH was prescribed for 77 % of patients and did not vary by BG distal anastomosis location or type. The 3-month cumulative incidence of TE was 5.1 % (95 % CI 1.4-12.6), including two BG occlusions, one DVT, and one myocardial infarction. Major bleeding occurred in 1 patient (1.28 %, 95 % CI 0.0-6.94). One patient died due to heart failure. TE and bleeding did not differ by bridging status. The 3-month cumulative incidence of TE among BG patients in whom warfarin is temporarily interrupted for an invasive procedure may be higher than in other "bridging" populations (atrial fibrillation, prosthetic heart valve, venous thromboembolism). This finding underscores the often tenuous nature of distal bypass grafts necessitating an aggressive approach to peri-procedural anticoagulation management.

KW - Bridging therapy

KW - Heparin

KW - Low molecular weight heparin

KW - Surgery

KW - Vascular bypass graft

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=84871803716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871803716&partnerID=8YFLogxK

U2 - 10.1007/s11239-012-0787-6

DO - 10.1007/s11239-012-0787-6

M3 - Article

C2 - 22843195

AN - SCOPUS:84871803716

VL - 35

SP - 100

EP - 106

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 1

ER -